Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM)‘s stock had its “buy” rating reaffirmed by equities researchers at Jefferies Group LLC in a research note issued to investors on Thursday. They presently have a $16.00 price objective on the biopharmaceutical company’s stock. Jefferies Group LLC’s target price would suggest a potential upside of 36.52% from the stock’s current price.

A number of other equities analysts also recently issued reports on BLCM. Ladenburg Thalmann Financial Services set a $31.00 price objective on shares of Bellicum Pharmaceuticals and gave the company a “buy” rating in a research note on Saturday, June 24th. Cantor Fitzgerald set a $32.00 price objective on shares of Bellicum Pharmaceuticals and gave the company a “buy” rating in a research note on Saturday, June 24th. Wells Fargo & Company reiterated an “outperform” rating and set a $31.00 price objective on shares of Bellicum Pharmaceuticals in a research note on Tuesday, June 27th. Raymond James Financial, Inc. reiterated a “buy” rating on shares of Bellicum Pharmaceuticals in a research note on Tuesday, June 27th. Finally, BidaskClub downgraded shares of Bellicum Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, July 6th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $26.20.

Shares of Bellicum Pharmaceuticals (NASDAQ:BLCM) opened at 11.72 on Thursday. Bellicum Pharmaceuticals has a 12 month low of $7.41 and a 12 month high of $23.11. The company’s market capitalization is $389.41 million. The stock has a 50 day moving average price of $9.50 and a 200-day moving average price of $11.71.

Bellicum Pharmaceuticals (NASDAQ:BLCM) last released its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.74) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.65) by ($0.09). Bellicum Pharmaceuticals had a negative net margin of 17,957.31% and a negative return on equity of 70.74%. During the same quarter in the prior year, the company earned ($0.61) EPS. Analysts forecast that Bellicum Pharmaceuticals will post ($3.02) EPS for the current year.

TRADEMARK VIOLATION WARNING: This article was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be viewed at https://www.thecerbatgem.com/2017/09/16/bellicum-pharmaceuticals-inc-blcm-rating-reiterated-by-jefferies-group-llc.html.

In other Bellicum Pharmaceuticals news, insider David M. Spencer sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, July 10th. The shares were sold at an average price of $11.54, for a total value of $115,400.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Ken Moseley sold 13,823 shares of the firm’s stock in a transaction that occurred on Thursday, July 13th. The shares were sold at an average price of $12.26, for a total transaction of $169,469.98. Following the completion of the sale, the vice president now owns 14,314 shares of the company’s stock, valued at $175,489.64. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 24,260 shares of company stock worth $290,048. Insiders own 23.30% of the company’s stock.

A number of institutional investors and hedge funds have recently made changes to their positions in BLCM. Ronald Blue & Co. LLC acquired a new stake in Bellicum Pharmaceuticals in the second quarter valued at approximately $117,000. Clear Harbor Asset Management LLC acquired a new stake in Bellicum Pharmaceuticals in the second quarter valued at approximately $118,000. Knott David M acquired a new stake in Bellicum Pharmaceuticals in the first quarter valued at approximately $131,000. Voya Investment Management LLC acquired a new stake in Bellicum Pharmaceuticals in the second quarter valued at approximately $132,000. Finally, American International Group Inc. boosted its stake in Bellicum Pharmaceuticals by 7.1% in the first quarter. American International Group Inc. now owns 12,902 shares of the biopharmaceutical company’s stock valued at $159,000 after acquiring an additional 852 shares in the last quarter. Institutional investors own 55.73% of the company’s stock.

Bellicum Pharmaceuticals Company Profile

Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.

Analyst Recommendations for Bellicum Pharmaceuticals (NASDAQ:BLCM)

Receive News & Stock Ratings for Bellicum Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.